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Abstract
Carcinogenesis is thought to occur through a combination of mutational and epimutational events that disrupt key
pathways regulating cellular growth and division. The DNA methylomes of cancer cells can exhibit two striking
differences from normal cells; a global reduction of DNA methylation levels and the aberrant hypermethylation of
some sequences, particularly CpG islands (CGIs). This aberrant hypermethylation is often invoked as a mechanism
causing the transcriptional inactivation of tumour suppressor genes that directly drives the carcinogenic process.
Here, we review our current understanding of this phenomenon, focusing on how global analysis of cancer methy-
lomes indicates that most affected CGI genes are already silenced prior to aberrant hypermethylation during
cancer development.We also discuss how genome-scale analyses of both normal and cancer cells have refined our
understanding of the elusive mechanism(s) that may underpin aberrant CGI hypermethylation.
Keywords: epigenetics; epigenomics; cancer; DNA methylation; CpG islands
INTRODUCTION
It is widely accepted that carcinogenesis necessitates
multiple genetic alterations that either drive cellular
division or remove checkpoints regulating this pro-
cess in normal cells. These same disruptions could
potentially also be caused by epimutations.
Epigenetic events have been strictly defined as her-
itable changes in gene function that are not ex-
plained by changes in DNA sequence but also
more recently as ‘the structural adaptation of
chromosomal regions so as to register, signal or per-
petuate altered activity states’ [1]. Here, we refer to
epimutations as heritable, abnormal alterations in the
state of chromosomal regions.
Strong support for the possibility that epimutations
play a significant role in cancer comes from the recent
discovery that epigenetic regulators are recurrently
mutated in cancer genomes and observations that
the levels and distributions of epigenetic marks are
altered in cancer [2]. Particular attention and research
effort has focused on the hypothesis that aberrant
silencing of genes by DNA hypermethylation is a
key epimutational mechanism driving carcinogenesis.
Importantly, a clear mechanism has been described for
the inheritance of DNA methylation patterns across
cellular generations [1] and, therefore, abnormal
DNAmethylation states fit the definition of epimuta-
tions as heritable alterations.
In normal mammalian somatic genomes, DNA
methylation mainly occurs at cytosines in a CpG di-
nucleotide context [3]. Around 70% of CpGs in
mammalian genomes are methylated but DNA
methylation is bimodally distributed and is generally
absent from short stretches of CpG-rich sequence
known as CpG islands (CGIs) [4] which frequently
correspond to the promoters of genes [5] (Figure 1A).
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The remainder of the genome is relatively depleted in
CpGs due to the inherent mutability of methylcyto-
sine (mC) which is prone to spontaneous deamination
[6]. Such deamination can also cause cancer-
associated mutations, including manyTP53 (p53) mu-
tations [7]. Methylated cytosines in the genome are
recognised by methyl CpG binding proteins (MBDs)
which are hypothesised to play an important role in
reading this epigenetic mark [8]. During embryogen-
esis, the mammalian genome undergoes a series of
epigenetic reprogramming events including a wave
of global demethylation followed by establishment
of the bimodal pattern by the de novo methyltrans-
ferases DNMT3A and DNMT3B [9]. The mainten-
ance DNA methyltransferase, DNMT1, ensures that
this distribution is stably inherited during the remain-
der of development and differences in the DNA
methylation profiles between adult cell types have
been shown to be relatively small, particularly at
CGIs which are generally maintained in a hypo-
methylated state regardless of gene expression status
[10, 11]. Regions bordering CGIs in the human
genome, termed CGI shores, have been suggested
to be more variably methylated between different
normal cell types [12, 13]. At present, however, it is
unclear whether they represent a distinct functional
genomic compartment. Hydroxymethylation of
cytosines (hmC) has also been recently rediscovered
in mammalian cells [14] and significant levels of this
modification are present in the bodies of active genes
in some somatic tissues [15].
In cancer cells, genomic levels of DNA methyla-
tion are frequently reduced compared with their
normal counterparts [16]. The underlying cause(s)
of this reduction is unknown, but the loss can be
localised to particular types of repetitive elements
[17] or chromosomal domains [18, 19] (Figure 1B).
Global levels of hydroxymethylation have also re-
cently been shown to be reduced in cancer cells
[15, 20–22]. Contrasting with this overall trend,
many CGIs undergo cancer-associated aberrant
hypermethylation [18] (Figure 1B). Hyperme-
thylation of CGI promoters is tightly linked with
transcriptional repression of the affected gene [23]
and many promoters initially shown to be aberrantly
hypermethylated in cancer correspond to known
tumour suppressor genes (TSGs) [24]. Aberrant
CGI hypermethylation has, therefore, been viewed
as an epimutation causing the silencing of TSGs
(Figure 2A) [25]. Thus, a strong hypothesis is that
the aberrant hypermethylation of CGIs can drive
carcinogenesis and cancer progression and that epi-
mutational events might outnumber mutations in
cancer [26].
Here, we review our current understanding of
aberrant CGI hypermethylation as a paradigm of a
potential epimutation in cancer. In particular, we
focus on how recent data from the study of cancer
methylomes demonstrates that the majority of genes
that are aberrantly hypermethylated in cancer are in
fact already repressed in preneoplastic cells. This par-
allels the view that most CGI hypermethylation in
Figure 1: The methylation landscape of normal and cancerous cells. (A) The mammalian genome is depleted of
CpGs and the majority of these are methylated (black lollipops). CGIs are rich in CpGs, frequently coincide with
gene promoters and are generally unmethylated (white lollipops), irrespective of gene expression status. The
bodies of active genes are enriched in hydroxymethylated CpGs (grey lollipops). (B) Both DNA methylation and
hydroxymethylation are reduced in cancer genomes but some CGIs become aberrantly hypermethylated.
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normal development occurs subsequent to silencing
by other means. Based on these findings, we present
alternative hypotheses as to the impact of aberrant
CGI hypermethylation on the growth and develop-
ment of cancers. Finally, we describe how the
genome-scale analysis of cancer has advanced our
understanding of the potential molecular mechan-
isms behind this epigenetic reprogramming.
EVIDENCE FOR INACTIVATION
OF TUMOURSUPPRESSOR
GENES BYABERRANT
HYPERMETHYLATION
Evidence that aberrant CGI hypermethylation might
act as an epimutation directly driving carcinogenesis
is based primarily on studies of individual candidate
genes. The aberrant hypermethylation of genes such
as RB1 [27–30], MLH1 [31, 32] and BRCA1 [33],
whose mutation is associated with inherited cancer
predisposition [34], can be regarded as particularly
significant. Three important pieces of evidence sup-
port the view that aberrant hypermethylation in
cancer causes their silencing.
First, hypermethylation of TSGs has been
observed alongside inherited germline mutations
[35–37]. This suggests promoter hypermethylation
can directly substitute for genetic loss of heterozy-
gosity (LOH) as the second hit that completely dis-
able TSG activity. The evidence is particularly strong
in the case of CDNK2A (p16/ARF) where the
presence of a mutation in the first exon in a colon
cancer cell line facilitated the direct demonstration
that hypermethylation occurs only on the wild-type
allele [36]. In the majority of cases, however, such
analyses have not or cannot be conducted and it re-
mains to be demonstrated whether hypermethylation
frequently occurs in an allele-specific fashion. Recent
studies of BRCA1 have failed to observe instances of
LOH through hypermethylation, suggesting that it
might be a very rare event [38, 39].
Second, the tissue specificity of TSG hyper-
methylation in sporadic cancer overlaps with the
tissue-specific predispositions caused by inherited
mutations in these same genes. Inherited MLH1
mutations predispose to colorectal cancer and
MLH1 hypermethylation is largely limited to colo-
rectal tumours [40]. Similarly, BRCA1 mutations
predispose specifically to breast and ovarian cancer
and hypermethylation is limited to cancer of these
tissues [40]. Within particular tissues, the phenotypes
of cancers which have hypermethylated particular
TSGs can overlap with the specific phenotypes of
cases associated with inherited mutations in the
same gene. For example, RB1 mutated and hyper-
methylated retinoblastomas phenocopy each other
[37], colorectal tumours with either mutated or
hypermethylated MLH1 have microsatellite instabil-
ity (MSI) [32] and VHL hypermethylation occurs in
renal cancers of the clear cell histological subtype as
do VHL mutations [41]. Rare cases of inherited
methylation of MLH1 and MSH2 also confer a
predisposition to developing MSI colorectal cancer
as do mutations in these genes, although these
apparent epimutations are tightly associated with
genetic variants [42, 43]. The overlap between the
phenotype of mutated and hypermethylated cancers
is less clear in other cases. Carriers of BRCA1 muta-
tions develop particular types of breast cancer,
specifically estrogen receptor negative (ERve)
tumours that are often classified as belonging to
one of a few special histological types [44]. BRCA1
hypermethylation was reported to be more frequent
in medullary carcinomas which are ERve and
often occur in BRCA1 carriers, but is also observed
in mucinous carcinomas which are ERþve [33, 45,
46]. Subsequent studies have reported that BRCA1
hypermethylation is not specific to ERve breast
cancers [47] and that the gene expression profiles
of BRCA1 mutated and methylated cancers differ
[48]. BRCA1 hypermethylated serous ovarian adeno-
carcinomas also displayed a clinical course that was
Figure 2: Hypermethylation of driver and passenger
genes in carcinogenesis. (A) Aberrant hypermethylation
of CGIs is thought to cause the silencing of tumour
suppressor genes and drive carcinogenesis. (B) The ana-
lysis of cancer methylomes demonstrates the majority
of hypermethylated genes are repressed in preneoplas-
tic cells. Hypermethylation of these, passenger, genes
might be a surrogate of general epigenetic dysfunction
that occasionally results in hypermethylation and
repression of active driver genes. White lollipops -
unmethylated CpGs, black lollipops - methylated CpGs.
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more similar to BRCA1 wild type than BRCA1
mutant tumours [49]. It should be noted, however,
that inherited and somatic mutations in important
TSGs can be associated with different phenotypes.
For example, inherited mutations in CDNK2A
predispose to melanoma and pancreatic tumours
[34] but somatic CDNK2Amutations occur in a var-
iety of other cancer types including non-small cell
lung cancer [50].
The final strong piece of evidence underpinning
the causative role of aberrant DNA hypermethylation
in silencing tumour suppressor genes in cancer is that
they can be reactivated when methylation is removed
from their promoters. This is most often achieved by
treatment with the drug 50-aza-20-deoxycytidine
(5-Aza) which causes the degradation of DNMT1,
the maintenance methyltransfrase [51]. Treatment of
cancer cell lines with 5-Aza causes the reactivation of
hypermethylated VHL [41], MLH1 [32, 52] and
BRCA1 [53]. Also, genetic knockout or RNA-
mediated knockdown of DNMT results in activation
of previously hypermethylated CDNK2A in a colo-
rectal cancer cell line [54, 55]. These experiments,
however, do not examine the temporal sequence of
events causing gene silencing. Treatment of female
mammalian cells with 5-Aza causes the activation of
genes on the inactive X chromosome (Xi) [56], but
silencing of genes on the Xi precedes hypermethyla-
tion of gene promoters [57, 58] and can occur in the
absence of DNMTs [59, 60]. These observations
demonstrate that gene activation can occur upon ab-
lation of promoter hypermethylation even when the
hypermethylation was not the initial and causative
silencing event.
MOSTABERRANTLY
HYPERMETHYLATED CGI GENES
AREREPRESSED PRIORTO
HYPERMETHYLATION
The evidence for aberrant CGI hypermethylation as
a direct silencer of TSGs is mostly correlative leading
many to question its direct role in carcinogenesis
[61–64]. Although cancer-associated hypermethyla-
tion of a gene’s promoter has been invoked to
suggest it might possess tumour suppressor activity
[65], many aberrantly hypermethylated genes are
unlikely candidates as TSGs, for example, CALCA
(Calcitonin), the first gene reported to become
hypermethylated in cancer [66]. Early unbiased
studies of cancer methylomes made it clear that
large numbers of genes could be hypermethylated
in a single specimen [67]. The most dramatic cases
are cancers with CGI hypermethylator phentotypes
(CIMP), first described in colorectal tumours [68]
and more recently in cancers arising in other tissues
[69–72]. The frequency of aberrant hypermethyla-
tion has been used to suggest that epimutations
might be more significant than mutations in carcino-
genesis [26], but this is difficult to reconcile with
evidence suggesting that relatively few mutations
are likely to be required for carcinogenesis [34, 73].
In order for aberrant hypermethylation to directly
drive cancer by silencing genes, the affected genes must
be expressed prior to hypermethylation. Trans-
criptionally repressed genes have been known to
undergo hypermethylation in tissue culture for many
years [74]. Recent integrated analyses of cancer methy-
lomes together with gene expression data demonstrate
that transcriptionally repressed genes are in fact also the
predominant target of cancer-associated aberrant
hypermethylation (Figure 2B). By analysing the
methylation profiles of cancers derived from seven dif-
ferent tissue types, we have shown that genes which
are repressed in a lineage-specific fashion in normal
tissues become hypermethylated in cancers derived
from that tissue, whereas housekeeping or expressed
lineage-specific genes are resistant to hypermethylation
[40, 75]. A study of colon cancer found that 93% of
the genes hypermethylated in CIMP tumours had un-
altered expression in tumours compared with normal
tissue [76]. This suggests they are already repressed in
the normal colon because CGI hypermethylation is
tightly associated with transcriptional repression. One
explanation for the low correlation frequently
observed between gene expression changes and pro-
moter hypermethylation in cancer methylomes studies
is that the majority of affected genes are normally re-
pressed in the tissue studied [71, 77–81]. A comparison
of an osteosarcoma cell line to cultured mesenchymal
stem cells and osteoblasts also found that the majority
of aberrantly hypermethylated genes in the osteosar-
coma cell line were repressed in the normal cells ana-
lysed [82]. It is possible that hypermethylation prone
genes are expressed to a low level rather than repressed
in normal tissue [18] but background levels of hybrid-
isation to probes make it difficult to draw this conclu-
sion from microarray expression data. A recent and
comprehensive analysis of the normal expression of
RUNX3, which is frequently hypermethylated in
gastric cancers, conclusively demonstrated that it is
in fact never expressed in the cells that give rise to
Cancer-associated aberrant CpG island hypermethylation 177
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these tumours and supports the hypothesis that hyper-
methylation prone genes are fully repressed rather than
expressed to a low level [65].
These recent findings from the study of cancer
methylomes draw parallels with our understanding
of CGI hypermethylation during normal develop-
ment which, most evidence suggests, occurs
at genes already repressed through other mechanisms
[83, 84]. As noted above, the hypermethylation of
CGIs on the Xi in female cells occurs after
genes have already been silenced [57, 58]. Mice de-
ficient for the de novo methyltransferases initiate
X-inactivation normally [60] and genetic deletion
of Dnmt1 does not preclude X-inactivation but in-
stead results in sporadic reactivation of the Xi later in
development [59]. Repression of the paternal copy
of the imprinted Meg3 (Gtl2) promoter in mouse
development occurs prior to its hypermethylation
[85]. The CGI promoter of the pluripotency asso-
ciated transcription factor Oct-3/4 is also silenced
before becoming hypermethylated during differenti-
ation and functional studies implicate hypermethyla-
tion in stabilising its silencing [86, 87]. It is repressed
gene promoters that become hypermethylated
during the in vitro differentiation of mouse ES cells
[88] and silencing of a transgene in chicken erythroid
cells precedes its hypermethylation [89]. A stabilising
role for CGI hypermethylation is also supported by
observations that DNA methylation represents a bar-
rier to the reprogramming of somatic cell types to
induced pluripotent stem cells (iPS cells) [90] and
that its ablation increases reprogramming efficiency
[91]. Taken together, findings from the study of
cancer methylomes put cancer-associated aberrant
CGI hypermethylation in a similar framework to
CGI hypermethylation in normal development, as
a largely secondary event (Figure 2B).
DOEPIGENETIC EVENTS IN
CANCER FOLLOWADRIVER
ANDPASSENGERMODEL?
Although the analysis of cancer methylomes demon-
strates that the vast majority of genes whose CGI
promoters become hypermethylated in cancer are
repressed prior to hypermethylation, the possibility
remains that occasionally active genes become
hypermethylated and repressed (Figure 2). Such
genes have been termed epigenetic drivers [92, 93]
and the bulk of hypermethylated genes, which are
repressed in normal untransformed tissue, are hence
termed passengers, a nomenclature adopted from
studies of the mutational structure of cancer genomes
[94]. The integrative analyses described above do not
exclude the possibility that a small proportion of
hypermethylated genes might be active in the
tissue of origin [40, 76] and one study has suggested
that a significant proportion of genes hypermethy-
lated in an osteosarcoma cell line are active in normal
cells [82]. The estimation of the exact proportion of
normally active genes that are aberrantly hyper-
methylated in cancer is, however, complicated by a
number of issues. First, normal tissues consist of a
heterogenous mix of cell types and cancers often
originate from rare cell populations, and therefore,
the bulk expression profile of a normal tissue might
not be representative of a cancer’s cell of origin [95].
Second, in these analyses, one measurement of
expression level is generally used for the whole
gene. The existence of alternative promoters, how-
ever, means that hypermethylation of an apparently
active gene may actually occur at an inactive pro-
moter, as has been described for APC in gastric
cancer [96]. Clarification of this situation will require
the analysis of rigorously purified cell populations
using techniques that measure promoter transcrip-
tional activity, such as CAGE [97], and carefully
constructed bioinformatic analysis pipelines which
focus on promoters rather than whole genes.
The strong phenotype of cancer predisposition
genes which are also hypermethylated [32, 33] dem-
onstrates that they must be expressed in the affected
normal tissues. A key question in these cases is
whether their aberrant hypermethylation is also sec-
ondary? The potential primary repressive event would
have to occur abnormally rather than as part of normal
development, as is the case for the majority of aber-
rantly hypermethylated genes. MLH1 is frequently
hypermethylated in colorectal tumours with a
CIMP phenotype [76] supporting the possibility
that MLH1 becomes hypermethylated through the
same mechanism affecting passenger genes. BRCA1
is repressed in sporadic breast cancer in the absence
of hypermethylation [47] suggesting that it too could
be repressed prior to hypermethylation. Silencing of
BRCA1 in cell lines can be initiated by the transcrip-
tion factors SNAI1 and SNAI2 (Snail and Slug,
respectively) in partnership with the histone lysine
demethylase LSD1 [98]. An interesting example is
CDKN2A which is frequently hypermethylated in a
variety of tumour types [99]. CDKN2A is normally
only expressed in cells following replicative or
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oncogenic stress and it remains silent in most normal
cells [100]. This suggests the possibility that the gene
could become hypermethylated prior to transform-
ation. CDKN2A is normally repressed by polycomb
repressive complexes (PRCs) [101, 102] which have
been implicated as part of the mechanism associated
with aberrant hypermethylation (see below).
Furthermore, after reactivation following genetic
knockout of DNMT1 and DNMT3B in a colon
cancer cell line, CDKN2A is silenced before DNA
hypermethylation is re-established [103] and
CDNK2A silencing also occurs prior to hypermethy-
lation in colonies of human mammary epithelial cells
(HMECs) that escape replicative arrest in culture
[104].
Taken together, these observations suggest that
although some hypermethylated genes might be
expressed in normal tissues, their hypermethylation
could follow aberrant down-regulation by other
means. Another possibility is that separate mechan-
isms result in the hypermethylation of active and
repressed genes. A recent study demonstrated that
the hypermethylation of initially active genes on
the Xi requires additional factors compared with
initially silent genes supporting the idea that alterna-
tive mechanisms might underpin the hypermethyla-
tion of different gene types [105]. Non-coding
genetic variants may also cause aberrant CGI hyper-
methylation, as exemplified by cases of inherited
allelic hypermethylation of MLH1 and MSH2
which are tightly associated with sequence variants
[42, 43]. The case of CDNK2A suggests that prior
expression in normal tissue is not a perquisite for the
hypermethylation of a gene playing a role in
promoting carcinogenesis. Also, even in cases of
driver genes where hypermethylation was not the
initiating silencing event, its role in maintaining
silencing might be important for the continued
growth of the cancer. Potential epigenetic driver
genes have been identified by screening for genes
whose promoters remain aberrantly hypermethylated
after genetic ablation of DNA methyltransferase
activity in a hypomorphic colorectal cancer cell
line [106]. The identified genes were not classically
known to be TSGs and their expression in normal
colon was not demonstrated but their enforced
expression via a strong CMV promoter in wild-type
colon cancer cell lines inhibited their growth
suggesting that maintenance of hypermethylation at
these genes was important for the fitness of the
cell line.
While the potential that the hypermethylation of
some genes is subject to positive selection because it
facilitates carcinogenesis fits current data from
methylome studies, a number of questions remain.
One prediction of the driver and passenger model is
that tumours with methylator phenotypes would
demonstrate more aggressive clinical behaviour
because they would be statistically more likely to
have hypermethylated more TSGs or drivers.
Methylator phenotypes in colorectal tumours,
breast tumours and glioblastomas, however, all coin-
cide with better clinical prognoses [69, 71, 107]. It
also remains to be explained why the mutational and
hypermethylation landscapes are so different if the
selection of rare driver events underpins their devel-
opment. Putative passengers, that is to say the
majority of aberrantly hypermethylated genes, are
frequently and reproducibly hypermethylated in
cancer whereas the strongest candidates for driver
genes, those that confer cancer predisposition when
mutated, are hypermethylated much more rarely
[40]. This contrasts with the mutational landscape
of cancer where individual driver genes are observed
to be more frequently mutated in clinical samples
than passenger genes as a result of selection [108].
ALTERNATIVE HYPOTHESESAS
TOTHEROLEOFABERRANTCGI
HYPERMETHYLATION INCANCER
Rather than playing an evolutionary neutral passenger
role and representing a surrogate of general epigenetic
dysregulation, the widespread hypermethylation of
normally repressed genes in cancer could have other
impacts on carcinogenesis and progression. As dis-
cussed above, hypermethylation of CGIs in normal
development results in stable gene silencing and
prevents ectopic activation [83]. It is conceivable
that abundant promoter hypermethylation could
influence the epigenetic plasticity of cancer cells
with two possible outcomes.
Many groups have noted that genes repressed by
PRCs in embryonic stem (ES) cells are frequently
hypermethylated in cancer [109–111]. Other studies
have reported overlaps in the gene expression
profiles of ES cells and aggressive cancers [112]
which, at least in part, correspond to repression of
ES cell PRC targets in cancers [113]. Many of the
genes targeted by PRCs in ES cells are transcription
factors whose expression is key to lineage commit-
ment during differentiation [114]. Thus, it has been
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proposed that the frequent hypermethylation of ES
cell PRC targets in cancer might block differenti-
ation and maintain cancers in a stem-cell-like state
[111] (Figure 3A). In support of this hypothesis,
genes which are expressed late in murine-lung
differentiation are reported to be frequently hyper-
methylated in non-small cell lung cancer [115].
IDH1R132Hmutations correlate with a hypermethy-
lator phenotype in acute myeloid leukaemia (AML)
[70] and knock-in of this mutant into mouse haem-
atopoietic stem cells results in general hypermethyla-
tion and an apparent block to differentiation [116].
These mutations, however, result in the production
of an oncometabolite, 2-hydroxygluterate, which
affects the function of numerous cellular enzymes
[117, 118] and the differentiation block observed
in this study is not necessarily a result of CGI
hypermethylation. The hypothesis that widespread
hypermethylation maintains cancers in a aggressive
stem-cell-like state is also inconsistent with the
better clinical prognoses associated with cancer
hypermethylator phenotypes [69, 71, 107].
Instead of maintaining a stem-cell-like state, a
restriction of epigenetic plasticity induced by wide-
spread hypermethylation could act as a check on
cancer progression (Figure 3B). The dissemination of
cancer cells from the site of origin and their survival in
metastatic niches requires the activation of gene ex-
pression programs [119]. Resistance to therapy can
occur as a result of secondary activating mutations
[120, 121] and potentially through epigenetic gene
activation. The stable gene repression associated with
hypermethylation might provide a barrier to these
events resulting in an inhibition of cancer progression.
This hypothesis is more consistent with the better
prognosis associated with hypermethylator pheno-
types. Genes whose expression is associated with me-
tastasis are hypermethylated as part of a breast cancer
hypermethylator phenotype [69]. One potential pre-
diction of a hypermethylation protective model is that
aberrant CGI hypermethylation might occur as part of
a cellular defence mechanism. Intriguingly, cellular
senescence is associated with epigenetic alterations
but it is unclear at present whether these include the
widespread hypermethylation of CGIs [122]. If a cel-
lular defence mechanism does result in aberrant CGI
hypermethylation, it provides an alternative explan-
ation for the observation of CGI hypermethylation
in pre-cancerous lesions which is commonly presented
as evidence of the importance of epimutations in the
earliest stages of carcinogenesis [123].
Cancers are, however, very heterogenous with
respect to their genetic and epigenetic profile and
the environment in which they grow; the two
hypotheses outlined above may, therefore, reflect
differing roles of widespread aberrant hypermethyla-
tion in different cancer types or subtypes. They
both may even play a part in the same cancer at
different stages of progression. For example, a
hypermethylation-mediated block on differentiation
may promote the initial growth of a tumour but later
this restricted epigenetic landscape might prevent its
metastasis. Furthermore, neither of these hypotheses
is incompatible with the occasional hypermethyla-
tion of driver genes outlined above. Differentiating
these possibilities requires an understanding of the
mechanism responsible for aberrant CGI
hypermethylation.
THEMECHANISM(S) OF
ABERRANTCGI
HYPERMETHYLATION INCANCER
Although the mechanism(s) responsible for aberrant
promoter hypermethylation in cancer remains elu-
sive, potential hypotheses have emerged from gen-
ome-scale analyses of both normal and cancerous
cells. Two main types of mechanisms have been
proposed; active processes mediated by targeting of
specific factors to CGIs or passive mechanisms result-
ing from a loss of protection against de novo
methylation.
One hypothesis is that aberrant CGI hypermethy-
lation in cancer results from the over-expression or
increased activity of DNMTs. Such increases were
initially reported [124, 125] but are likely to be
attributed to the regulation of DNMTs during the
cell cycle [126, 127] and an increased number of
cycling cells in cancer. A recent analysis reports
that hypermethylation at some genes correlates
with increased DNTM3B levels in colorectal tu-
mours [128]. Experimental manipulation of
DNMT levels in the Apcmin/þ mouse model of colo-
rectal cancer demonstrate that higher DNMT levels
promote carcinogenesis [129–131]. Dnmt3b over-
expression in this model is also associated with
promoter hypermethylation of the murine homo-
logues of genes hypermethylated in human colorec-
tal tumours [132]. On the other hand, DNMT3A
mutations occur in AML and other haematological
cancer genomes [133, 134] and these mutations have
been shown to reduce DNMT3A enzymatic activity
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[135]. They have not, however, been found to cor-
relate with variations in CGI hypermethylation
patterns [133, 136]. DNMT3B mutations in cancer
have not currently been found but aberrant splicing
of DNMT3B frequently gives rise to cancer-specific
isoforms of the enzyme [137]. These isoforms lack a
methyltransferase domain but they could potentially
function similarly to DNMT3L, acting as cofactors to
bring canonical DNMT3A and 3B to new locations
and stimulating their activity [138, 139]. Although
variations in DNMT activity might affect carcino-
genesis, it remains to be demonstrated whether this
Figure 3: Models as to the consequences of widespread CGI hypermethylation in cancer. (A) Hypermethylation as
a block to differentiation. This model predicts that key genes required for normal cellular differentiation become
hypermethylated in cancer. The result is a block to their activation and thus normal differentiation processes
within the cancer producing a more aggressive, stem-cell like phenotype. (B) Hypermethylation as a block to
progression. Widespread hypermethylation of repressed CGI promoters might prevent their stochastic activation
in individual cancer cells. If the activation of such genes facilitated survival in changing conditions, such as during
metastasis to distant organs or treatment, widespread hypermethylation might restrict the potential for epigenetic
adaptation and thus result in block to progression.
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occurs as a result of increased CGI hypermethylation.
It is also unclear as to whether MBDs play any role in
the process of aberrant CGI hypermethylation. The
MBDs Mbd2 and Kaiso appear have contributary
roles in intenstinal tumorogenesis as their deletion
in mice result in reduced tumour numbers in
Apcmin/þ mice [140, 141]. As with the DNMT
work described above, however, these phenotypes
have not been shown to be connected to aberrant
CGI hypermethylation and currently no mutations
in MBDs have been described in cancer.
As noted above, genes marked by PRCs in ES
cells are frequently hypermethylated in cancer.
DNMT3A and 3B biochemically interact with
EZH2, a member of the PRC2 complex [142], lead-
ing to the suggestion that PRCs might recruit
DNMTs to aberrantly hypermethylated genes. This
interaction has, however, been reported to be cell
type-specific [143] and artificial recruitment of
EZH2 to a genomic locus does not result in hyper-
methylation [144]. DNA methylation and the PRC-
associated histone mark, H3K27me3, rarely overlap
at gene promoters [145, 146] and direct bisulfite
sequencing of material from chromatin immunopre-
cipitation (ChIP) demonstrates that H3K27me3 and
DNA methylation do not co-occur at CGIs [147,
148]. Recent evidence suggests that DNA methyla-
tion may restrict PRC distribution [148, 149], at least
in ES cells, but there is currently no direct evidence
to suggest the opposite scenario; i.e. CGIs are
protected from hypermethylation by PRC occu-
pancy. H3K27me3-marked CGIs that become
hypermethylated in cancer have, however, been
reported to lose this histone mark [150].
Histones and their associated marks may play
other roles in protecting CGIs from hypermethyla-
tion. In normal cells, the histone mark H3K4me3 is
anti-correlated with DNA methylation [151].
H3K4me3 is intimately associated with CGIs due
to the presence of Cfp1 which recruits Set1, a
H3K4 methylase [152]. DNMT activity during
early development is directly inhibited by
H3K4me3 because DNMT3L cannot bind histones
carrying this mark [153] but Cfp1 knockout in mouse
ES cells does not result in CGI hypermethylation
[154]. The variant histone H2A.Z is also
anti-correlated with DNA methylation in plants
[155], fish [156] and human cells [157]. Mutation
of the enzyme responsible for H2A.Z deposition in
plants results in gains of methylation [155] but the
mechanistic basis for this relationship however
remains unknown and no somatic defects in
H2A.Z have been reported in cancer.
The analysis of cancer methylomes has also linked
dysfunction in DNA demethylation pathways to ab-
errant CGI hypermethylation. DNA demethylation
is proposed to be initiated by the conversion of mC
to hmC by the ten-eleven translocation (TET)
family of enzymes [158, 159]. Tet1 is bound to
CGIs in mouse ES cells [160, 161] leading to the
proposal that it maintains the fidelity of DNA
methylation patterns in cells by maintaining CGIs
in a hypomethylated state [162]. As noted above,
reduction in global hmC is frequent in cancer [15,
20–22] and disruptions to TET enzyme function
have been linked to CGI hypermethylation.
Mutations abrogating TET2 enyzmatic activity are
frequent in AML [163] and correlate with a hyper-
methylator phenotype [70]. The oncometabolite
2-hydoxygluterate is also produced in AMLs with
IDH1 or 2 mutations and one of its effects is the
inhibition of TET enzyme activity [118]. IDH
mutations in AML correlate with a similar hyper-
methylator phenotype to TET2 mutations [70] and
CIMP in glioblastoma is also associated with IDH1
mutations [71]. Although one study suggested Tet1
knockdown in mouse ES cells led to CGI hyper-
methylation [161], the same observation was not
made in a similar independent study [160]. As
TET1 is also bound to the vast majority of CGIs
in mouse ES cells, it is unclear why TET dysfunction
in cancer might result in the preferential hyper-
methylation of repressed CGIs.
Epigenomic analyses of normal cells point
towards DNA sequence determining genome
methylation patterns through sequence-specific
transcription factors (TFs) rather than vice versa
[164–166]. DNMT3A and 3B have been shown to
interact with normal TFs [167] and abnormal ver-
sions generated as a result of gene fusions [168].
Although a number of studies have published
sequence motifs associated with genes that become
hypermethylated in cancer, these have neither been
reproduced nor demonstrated to correspond to the
binding sites of particular TFs [78, 169]. As TFs are
found at both active and repressed genes, it is unclear
why their recruitment of DNMT would specifically
result in the hypermethylation of repressed genes.
A reproducible association does occur between gen-
eral TF motifs and hypermethylation-resistant
promoters [18, 170] which is consistent with their
housekeeping gene status [40]. In addition to
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suggesting that TF binding protects CGIs from
hypermethylation, this correlation could be ex-
plained if transcriptional activity itself conferred pro-
tection from hypermethylation. One model for the
generation of bimodal hypermethylation patterns in
mammalian cells postulates that CGIs are protected
from de novo methylation by transcription during the
developmental window in which the genome is
remethylated [63]. An analysis comparing normal
and cancer cell lines also showed that the presence
of stalled or active RNA polymerase in normal cells
predicts resistance to aberrant hypermethylation in
cancer cells [171]. Variations in DNA sequence
that alter promoter activity also correlate with the
predisposition of promoters to hypermethylation.
An extra SP1 site in the RIL gene confers resistance
to hypermethylation [172] and sequence variants in
the MLH1 promoter that reduce promoter activity
are associated with soma-wide mosaic hypermethy-
lation [42]. It is unclear, however, if low-level tran-
scription confers resistance to CGI hypermethylation
or whether the relationship is quantitative with
increasing transcription levels resulting in a lower
frequency of hypermethylation but not entirely
excluding it. Models of protection based on the
hypothesis that transcription protects CGIs must
also consider the presence of stalled RNA polymer-
ase at PRC-marked genes [173, 174].
One of the main results to emerge from the
systematic analysis of cancer methylomes is the find-
ing that cancer-associated hypermethylation does not
occur at random but affects a distinct set of genes. As
noted above, several groups have documented the
overlap between PRC-marked genes in ES cells
and hypermethylation in cancer and this has been
reproduced extensively in genome profiling studies
[76, 109–111, 175]. Rather than being repressed,
PRC-occupied CGIs in ES cells are proposed to
exist in a poised state [176] which is resolved to
either full activation or repression as differentiation
proceeds [177]. A subset of PRC-marked genes in
ES cells are, therefore, expected to be occupied by
PRCs in differentiated cell types. The association
between PRC-marked CGIs in ES cells and hyper-
methylation in cancer might, therefore, reflect pref-
erential hypermethylation of those repressed CGIs
associated with PRCs in adult cells during the trans-
formation process rather than a mechanistic connec-
tion between ES cell and cancer epigenetic state.
The promoters of hypermethylation-prone genes
are also relatively depleted of retrotransposons
compared with hypermethylation-resistant pro-
moters [178]. This could result from evolutionary
selection against retrotransposon integration near
tissue-specific genes because it might disrupt essential
interactions with distal regulatory elements [40].
Overall, the characteristics of hypermethylation-
prone genes are consistent with the possibility that
repressed, lineage-specific genes are predominantly
subject to cancer-associated hypermethylation [40].
While the observation that aberrant hypermethyla-
tion affects a specific set of genes has been presented
as evidence for a targeted rather than stochastic pro-
cess of hypermethylation [179], it does not exclude
the possibility that stochastic hypermethylation
occurs with a susceptible set of genes. One recent
study has suggested that normal cell line promoter
methylation patterns evolve through a stochastic
process [180].
Taken together, these studies suggest that many
factors could be involved in the reprogramming of
repressed CGIs to a hypermethylated state in cancer.
It is clear that a number of different factors found at
active CGI promoters are capable of maintaining
them in a hypomethylated state including
H3K4me3, H2A.Z, TFs, TET enzymes and active
RNA transcription (Figure 4A). Repressed CGIs are
also occupied by a number of factors that could po-
tentially perform the same function including TETs,
PRCs and RNA polymerase (Figure 4B).
Furthermore, some of these factors are shared with
active CGIs, so it is uncertain why a defect in any
one factor would result in aberrant CGI hyper-
methylation (Figure 4B). The potential role of
active recruitment of DNMTs in this picture is also
unclear and the relative importance of stochastic and
targeted processes in the evolution of cancer CGI
methylomes remains to be determined.
SUMMARYANDCONCLUSIONS
The recent characterisation of cancer methylomes
has demonstrated, contrary to the prevailing view,
that the hypermethylation of CGI promoters in
cancer parallels CGI hypermethylation during
normal development and is secondary to silencing
by other means. For most aberrantly hypermethy-
lated promoters, this silencing occurs as a result of
normal development and subsequent methylation
represents an epigenetic reprogramming event.
Potential driver genes that are expressed in normal
cells could conceivably be directly silenced by
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aberrant hypermethylation. The overwhelming ten-
dency for hypermethylation to occur as a secondary
event, however, strongly suggests that such drivers
are subject to primary aberrant silencing in cancer
through other means. Hypermethylation of isolated
individual repressed genes may also contribute a
growth advantage to cancer by preventing their ac-
tivation at later stages of carcinogenesis or progres-
sion. We should also consider whether the
widespread hypermethylation of CGIs in cancer has
other impacts on the growth of cancers, in particular
by blocking differentiation or restricting epigenetic
plasticity and adaptive potential.
The analysis of cancer genomes and methylomes
have helped refine our definition of the type of gene
affected by aberrant promoter hypermethylation and
generated new hypotheses as to the molecular defect
underpinning this epigenetic reprogramming but
many questions remain to be answered. Dissection
of this mechanism is also likely to lead to new in-
sights regarding the biology of CGIs, the most abun-
dant promoter type in our genome [63]. The
reinterpretation of cancer-associated CGI hyper-
methylation that has occurred as a result of the
advent of genome-scale datasets should also be con-
sidered as potential epimutations associated with
other diseases are identified [181]. Finally, cancer
epigenomes are potentially a rich source of bio-
markers and specific epigenetic defects may be ex-
ploitable therapeutic targets [182]. We have not
discussed these avenues of research here, but our
new more global understanding of cancer-associated
Figure 4: Potential mechanisms of cancer-associated aberrant hypermethylation.CGIs bound are occupied by mul-
tiple factors that potentially play roles in aberrant CGI hypermethylation. (A) Nucleosomes incorporating the his-
tone variant H2A.Z and with H3K4me3 marks, TFs, active transcription and TET enzymes may all help maintain
the hypomethylated state of active CGIs in normal cells. TET enzyme function is most likely compromised in at
least some cancers but this still leaves other protective factors at active CGIs. (B) Similarly, a number of factors
are found at inactive CGIs that could potentially play a role in maintaining their normal hypomethylated state includ-
ing TET enzymes, PRCs and stalled RNA polymerase. PRCs are thought to be lost, most likely along with stalled
RNA polymerase, when CGIs become aberrantly hypermethylated, but it is unclear if this plays a mechanistic role
in this cancer-associated epigenetic reprogramming. The role of DNMTrecruitment in the process is also unclear.
White lollipops - unmethylated CpGs, black lollipops - methylated CpGs.
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CGI hypermethylation should be used to guide these
efforts.
As this review was going to press, de-repression of
CXCR4, which has a CGI promoter, was shown to
facilitate metastasis in a renal cancer cell line [183].
This further supports our proposal that widespread
aberrant hypermethylation of CGI promoters in
cancer could inhibit progression by blocking gene
activation (Figure 3).
Key Points
 CpG islands (CGIs) frequently become aberrantly hypermethy-
lated in cancers.
 Analysis of cancer methylomes has shown that aberrant CGI
hypermethylation occurs primarily at genes that are already
silent in the host tissue and is therefore not generally linked to
transcriptional silencing of tumour suppressor genes.
 The predominant view is that CGI hypermethylation in normal
development is also secondary to prior silencing through other
mechanisms.
 Several hypotheses now exist as to the impact of CGI hyper-
methylation on carcinogenesis and progression. The occasional
hypermethylation of rare driver genes might directly promote
carcinogenesis. Widespread CGI hypermethylation could also
result in more aggressive cancers by blocking cellular differenti-
ation or act as a protective mechanism hindering progression
by preventing epigenetic adaptation to changing conditions.
 Themechanism underpinning aberrant CpG island hypermethy-
lation remains elusive but genome-scale studies have refined
our hypotheses and demonstrated that a distinct gene set is
affected.
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